Anbio Biotechnology Class A Ordinary Shares (NNNN) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate Anbio Biotechnology Class A Ordinary Shares's investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
187.94
Weak
WeakModerateStrong
P/B Ratio
43.77
Weak
WeakModerateStrong
Earnings Yield
0.49%
Yield Trap
WeakModerateStrong
Profitability Health
2025Return on Equity
21.24%
Strong
WeakModerateStrong
Operating Margin
66.70%
Strong
WeakModerateStrong
Net Profit Margin
74.06%
Strong
WeakModerateStrong
Growth Indicators
2025Revenue Growth
5.64%
Moderate
WeakModerateStrong
Net Income Growth
169.86%
Strong
WeakModerateStrong
EPS Growth
185.71%
Strong
WeakModerateStrong
Efficiency & Liquidity
2025Current Ratio
344.31
Strong
WeakModerateStrong
Quick Ratio
344.31
Strong
WeakModerateStrong
Asset Turnover
0.29x
Weak
WeakModerateStrong
Inventory Turnover
-
No data
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
-0.51%
Weak
WeakModerateStrong
EV / Free Cash Flow
-194.69x
Strong
WeakModerateStrong
Net Debt / EBITDA
-1.35x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
1.110
Strong
WeakModerateStrong
Return on Invested Capital
19.13%
Moderate
WeakModerateStrong
Cash Conversion Cycle
154.37 days
Weak
WeakModerateStrong
Fortress screener guardrails
1/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for NNNN.
View Financial Statements